Suven receives product patents

June 13, 2017 10:04 pm | Updated 10:04 pm IST - HYDERABAD

Suven Life Sciences Ltd. has recieved one product patent each from Australia and the U.S. corresponding to new chemical entities for treatment of disorders associated with neurodegenerative diseases. The patents are valid through 2032 and 2034 respectively. The molecules are being developed as therapeutic agents and are useful in treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia, Suven said.

“We are very pleased by the grant of these patents to our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” CEO Venkat Jasti said.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.